Brief: Alzamend Neuro Submits Ind Application For Phase I/Iia Trial For An Immunotherapy (Alzn002) To Treat Mild To Moderate Dementia Of The Alzheimer’s Type
29/09/2022 13:26
Sept 29 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO SUBMITS IND APPLICATION FOR PHASE I/IIA
TRIAL FOR
AN IMMUNOTHERAPY (ALZN002) TO TREAT MILD TO MODERATE DEMENTIA OF
THE ALZHEIMER’S TYPE
Source text for Eikon: ID:nBwb29crGa
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview